MLchartDataset catalogue

Copper Cu 64-DOTA-AE105

Term · Oncology and biomedicine · MLC-T-ONC-012757

A radiotracer composed of AE105, a urokinase-type plasminogen activator receptor (uPAR) peptide antagonist, conjugated with DOTA and labeled with the radionuclide copper Cu 64, with potential imaging activity upon positron emission tomography (PET). Upon administration, the AE105 moiety of copper Cu 64-DOTA-AE105 targets and binds to uPAR-expressing tumor cells. Upon PET imaging, the copper Cu 64 moiety can be visualized, uPAR-expressing tumor cells can be quantified and the degree of tumor aggressiveness can be assessed. uPAR expression is correlated with increased tumor invasiveness and aggressiveness as well as a poor prognosis.

Table 1. Record
IdentifierMLC-T-ONC-012757
FieldOncology and biomedicine
Synonyms64Cu-DOTA-AE105
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-012757",
  "term": "Copper Cu 64-DOTA-AE105",
  "field": "Oncology and biomedicine",
  "definition": "A radiotracer composed of AE105, a urokinase-type plasminogen activator receptor (uPAR) peptide antagonist, conjugated with DOTA and labeled with the radionuclide copper Cu 64, with potential imaging activity upon positron emission tomography (PET). Upon administration, the AE105 moiety of copper Cu 64-DOTA-AE105 targets and binds to uPAR-expressing tumor cells. Upon PET imaging, the copper Cu 64 moiety can be visualized, uPAR-expressing tumor cells can be quantified and the degree of tumor aggressiveness can be assessed. uPAR expression is correlated with increased tumor invasiveness and aggressiveness as well as a poor prognosis.",
  "synonyms": [
    "64Cu-DOTA-AE105"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/copper-cu-64-dota-ae105/"
}

Record 5,307 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.